Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Watanabe Todd Franklin | | | | | | 2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT] | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | |
|--|---|-----|----------|-----------|---|--|---|---|---|---|--------------------|--|--------------------------------|---|--|---|---|---------------------------------------|
| | | | | | | | | | | | | | | | 045.0 | | | |
| (Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC. | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/06/2022 | | | | | | | | X | Officer (give title Other (specify below) below) President and CEO | | | | |
| 3027 TOWNSGATE ROAD, SUITE 300 | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
| (Street) | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Inc | ndividual or Joint/Group Filing (Check Applicable e) | | | | |
| WESTLAKE CA 91361 | | | | | | | | | | | | | X | Form | Form filed by One Reporting Person | | | |
| VILLAGE OF THE STATE OF THE STA | | | | | | | | | | | | | | | Form filed by More than One Reporting Person | | | |
| (City) | City) (State) (Zip) | | | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | | Exec if an | . Deemed ecution Date, iny onth/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5) | | | | 5. Amount of Securities Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | | | | Code | v | Amount | (A) (D) | or P | rice | | ed ction(s) 3 and 4) | | (Instr. 4) |
| Common Stock 07/06/ | | | | | 2022 | 022 | | | S ⁽¹⁾ | | 1,000 | D | | \$22.07 | | 3,284(2) | D | |
| Common Stock | | | | | | | | | | | | | | 51 | 7,358 | I | By LLC ⁽³⁾ | |
| Common Stock | | | | | | | | | | | | | | | 1′ | 7,850 | I | By Trust ⁽⁴⁾ |
| Common Stock | | | | | | | | | | | | | | 17,850 | | I | By Trust ⁽⁵⁾ | |
| Common Stock | | | | | | | | | | | | | | 124,956 | | I | By Trust ⁽⁶⁾ | |
| | | Tal | ble II - | Derivati | ve Se | curi | ties / | Acqu | ired, [| Disp | osed of, | or Be | nefi | cially | Owne | d | | |
| | | | | | | IIIS, V | | | | | onvertib | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any | | | ion Date, | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exerci Expiration Dat (Month/Day/Ye | | ite | 7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4) | | De Se (In | Price of erivative ecurity astr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4) | Ownershi Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exercis | able | Expiration Date | Title | Amo or Num of Shar | ber | | | | |

Explanation of Responses:

- 1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- 2. Includes 109,925 restricted stock units.
- 3. The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section
- 4. The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes
- 5. The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 6. The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes

/s/ Scott Burrows, as Attorney-in-Fact for Todd

07/07/2022

Franklin Watanabe

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.